2022年12月13日

在一项随机临床试验中，个性化MRNA癌症疫苗首次显示出令人印象深刻的疗效后，ArtemisDiana Moderna (NASDAQ: MRNA)股价周二飙升。该股在下午的交易中上涨了24%。凭借新型冠状病毒MRNA疫苗而声名鹊起的Moderna (MRNA)公司现在证明，MRNA技术不仅仅是对抗冠状病毒的一种手段，而且还可能成为癌症领域的颠覆者。它还可能为生物技术公司提供急需的提振，该公司今年迄今仍下跌了约13%。来自Moderna (MRNA)和默克(NYSE: MRK)的个性化癌症疫苗MRNA -4157/V940，与后者的重磅药物Keytruda (pembrolizumab)联合使用，在名为KEYNOTE-942的2b期研究中，与单独使用Keytruda相比，复发或死亡的风险降低了44%。该组合正在被评估为完全切除后3/4期黑色素瘤患者的辅助治疗。这项研究共有150人参加。Moderna已与Autolus Therapeutics公司(AUTL)合作，并于2021年8月通过授权协议获得了这家总部位于伦敦的公司的专有粘合剂，以开发最多4种免疫肿瘤靶点的mRNA疗法。除了MRNA -4157，根据11月3日美国证券交易委员会(SEC)的文件，该公司正在进行多个队列的一期试验，Moderna (MRNA)正在开发其癌症疫苗模式中的其他三个项目。根据申请文件，该公司拥有KRAS一期疫苗mRNA-5671，并保留了默克公司(Merck)对该疫苗的所有权利，并正在评估该项目的下一步工作。 Moderna's third program is a new checkpoint cancer vaccine candidate mRNA-4359, which has already dosed the first patient in a phase 1 trial. Merck ( MRK ) has been collaborating with Moderna ( MRNA ) since the past few years. While Merck ( MRK ) gave back rights to an RSV vaccine mRNA-1172 to Moderna ( MRNA ) in October 2020, the Kenilworth, N.J.-based pharma giant exercised an option this year in October to jointly develop and commercialize the cancer vaccine mRNA-4157/V940. The vaccine had also shown promise in preliminary results in a phase 1 trial in head and neck cancer. But the two companies are not the only ones in the race for cancer vaccines. Last month, German biotech CureVac's ( CVAC ) mRNA-based cancer vaccine CV8102 had shown preliminary efficacy as a combination therapy in patients with PD-1 refractory melanoma. Earlier Tuesday Gritstone bio ( GRTS ) stock surged after the company received two U.S. patents related to its self-amplifying mRNA (samRNA) vaccine platform technology. Several companies are in the run for exploring cancer vaccines, if not an mRNA cancer vaccine. Amazon.com ( AMZN ) has reportedly got into a research team up for cancer vaccines, while ImmunityBio ( IBRX ) has a combination immunotherapy (Nant Cancer Vaccine ) in pancreatic cancer in phase 2. VBI Vaccines ( VBIV ) is exploring VBI-1901 to treat glioblastoma, while Agenus ( AGEN ) and Targovax are collaborating on mutant KRAS cancer vaccines. Anixa Biosciences ( ANIX ) is developing a breast cancer vaccine technology and GeoVax Labs ( GOVX ) also has a cancer vaccine program . Meanwhile, Defence Therapeutics ( OTCPK:DTCFF ) has a program to use its Accum technology in engineering messenger (m)RNA vaccines targeting cancer. Meanwhile, Merck ( MRK ) is not just exploring the mRNA space. The company is also working on new investigational class of engineered circular RNA (oRNA) therapies for which it signed a licensing deal with Orna Therapeutics to discover multiple programs, including vaccines and therapeutics for infectious disease and oncology. Recommended For You